SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

Also called NCT06054035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06054035
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06054035. Randomized; double masking; primary purpose treatment. Start 2023-10-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Condition
Type2diabetes
Condition
PreDiabetes
Condition
Renal Failure
Intervention (Drug)
Dapagliflozin (Forxiga®)
Intervention (Drug)
Placebo matching Dapaglifolzin
Intervention (Behavioral)
Lifestyle Intervention
Lead sponsor
University Hospital Tuebingen (class: other)
Collaborator
German Federal Ministry of Education and Research (class: other government)
Collaborator
German Center for Diabetes Research (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06054035
Content hash
3c9e5c02ef460ee02fbade366960cd9bb6316a446d451ccfdc7bf793b76a9eaf